Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -6.76% is 1119% below its 2-year average of 0.66%, around the middle of its 2-year range (-18.90%–13.76%).
16.22% above its 12-month average of -8.07%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2026 (2026-03-31): -18.90%.
EBITDA MARGIN
-6.76%
EBITDA MARGIN AVG TTM
-8.07%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+16.22%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cellyan Biotechnology Co., Ltd
Market Cap
$1.10M
EBITDA Margin
-6.76%
TTM Avg
-8.07%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.12M
EBITDA Margin
-40873.19%
TTM Avg
-40873.19%
3Y Avg
-21172.28%
5Y Avg
-10780.34%
Market Cap
$1.14M
EBITDA Margin
-17.60%
TTM Avg
-16.25%
3Y Avg
-23.94%
5Y Avg
-32.10%
Market Cap
$1.03M
EBITDA Margin
-182712.72%
TTM Avg
-182712.72%
3Y Avg
-182712.72%
5Y Avg
-182712.72%
Market Cap
$885939.00
EBITDA Margin
1710.10%
TTM Avg
8440.35%
3Y Avg
4905.18%
5Y Avg
4832.78%
Market Cap
$848489.00
EBITDA Margin
-148.44%
TTM Avg
-191.64%
3Y Avg
-1422.24%
5Y Avg
-1921.61%
Market Cap
$873327.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellyan Biotechnology Co., Ltd (HKPD) | $1.10M | -6.76% | -8.07% | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.12M | -40873.19% | -40873.19% | -21172.28% | -10780.34% |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.14M | -17.60% | -16.25% | -23.94% | -32.10% |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.16M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | -182712.72% | -182712.72% | -182712.72% | -182712.72% |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | 1710.10% | 8440.35% | 4905.18% | 4832.78% |
| Decoy Therapeutics Inc. (DCOY)vs › | $848489.00 | -148.44% | -191.64% | -1422.24% | -1921.61% |
| Bone Biologics Corporation (BBLG)vs › | $873327.00 | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $825495.00 | -3618.46% | -3618.46% | -3618.46% | -3618.46% |
Gross Margin
10.3%
EBITDA Margin
-6.8%
Operating Margin
-7.4%
Net Margin
-8.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | -18.90% |
| 2025-09-30 | 3.95% |
| 2025-03-31 | -9.25% |
| 2024-09-30 | 9.57% |
| 2024-03-31 | 13.76% |
| 2023-09-30 | 4.86% |
